Search Results - "Langer, S.W"

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas by Galleberg, R.B, Knigge, U, Tiensuu Janson, E, Vestermark, L.W, Haugvik, S.-P, Ladekarl, M, Langer, S.W, Grønbæk, H, Österlund, P, Hjortland, G.O, Assmus, J, Tang, L, Perren, A, Sorbye, H

“…Abstract Background Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a…”
Get full text

9069 POSTER Randomized Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer – the MENZA Study by Grønberq, B, Ciuleanu, T, Flotten, O, Knuuttila, A, Abel, E, Langer, S.W, Munoz, M, Hahka-Kemppinen, M, Sundstrom, S

Get full text

Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice by Langer, S. W., Sehested, M., Jensen, P. Buhl

“…Summary Background: Recently, we have shown that dexrazoxane (ICRF-187) is an effective antidote against accidental extravasation of anthracyclines. Thus, it…”
Get full text

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study by Sorbye, H., Welin, S., Langer, S.W., Vestermark, L.W., Holt, N., Osterlund, P., Dueland, S., Hofsli, E., Guren, M.G., Ohrling, K., Birkemeyer, E., Thiis-Evensen, E., Biagini, M., Gronbaek, H., Soveri, L.M., Olsen, I.H., Federspiel, B., Assmus, J., Janson, E.T., Knigge, U.

“…As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers…”
Get full text

Anthracycline extravasation in breast cancer patients. Effective treatment with dexrazoxane in three multicenter trials by Mouridsen, H, Langer, S.W, Tjoernelund, J, Grundtvig, P, Buter, J, Knoblauch, P, Jensen, R.B

Get full text

Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence by Grøndahl, V., Binderup, T., Langer, S.W., Petersen, R.H., Nielsen, K., Kjaer, A., Federspiel, B., Knigge, U.

“…•Tumour type was the single most potent prognostic factor for survival in BP-NETs.•FDG-PET scans were mostly positive in all three subtypes of BP-NETs.•LCNEC…”
Get full text

Deep Inspiration Breath Hold Compliance in Radiation Therapy for Locally Advanced Lung Cancer by Persson, G.F., Aznar, M.C., Rydhög, J.S., Mortensen, S.R., Nygaard, L., Pøhl, M., Langer, S.W., Specht, L., Josipovic, M.

Get full text

PO-0773 CBCT is not valid for response evaluation after chemoradiotherapy for locally advanced NSCLC by Persson, G., Pøhl, M., Nygård, L., De Blanck, S.R., Scherman, J., Langer, S.W., Larsen, K. Richter, Clementsen, P.F., Specht, L., Fischer, B.M., Aznar, M.C., Josipovic, M.

Get full text

87P Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting by Krogshede, S.K., Buhl, I.K., Perino, L., Baudet, C., Yde, C.W., Clausen, M.M., Tuxen, I.E.V., Hoejgaard, M., Langer, S.W., Spanggaard, I., Rohrberg, K.S.

Get full text

Erratum to “Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence” [Lung Cancer 132 (June) (2019) 141–149] by Grøndahl, V., Binderup, T., Langer, S.W., Petersen, R.H., Nielsen, K., Kjaer, A., Federspiel, B., Knigge, U.

Get full text

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies by Mouridsen, HT, Langer, SW, Buter, J, Eidtmann, H, Rosti, G, de Wit, M, Knoblauch, P, Rasmussen, A, Dahlstrøm, K, Jensen, PB, Giaccone, G

“…Background: The purpose of this study was to assess the efficacy and tolerability of i.v. dexrazoxane [Savene™ (EU), Totect™ (US)] as acute antidote in…”
Get full text

A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis by Fischer, B.M., Mortensen, J., Langer, S.W., Loft, A., Berthelsen, A.K., Petersen, B.L., Daugaard, G., Lassen, U., Hansen, H.H.

“…Background: Small-cell lung cancer (SCLC) accounts for 15%–20% of all lung cancer cases. Accurate and fast staging is mandatory when choosing treatment, but…”
Get full text

The catalytic topoisomerase II inhibitor dexrazoxane inhibits anthracycline-induced necrosis in mice: A new treatment of accidental extravasation of anthracyclines by Langer, S.W, Sehested, M, Jensen, P.B

Get full text

Targeting the cell kill of etoposide to brain metastases. A method for prophylactic cranial chemotherapy (PCC) in small cell lung cancer by Jensen, P.B, Langer, S.W, Sehested, M

Get full text

Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory by Jensen, P.B., Sehested, M., Langer, S.W., Hansen, H.H.

Get full text